GSK’s bone cancer treatment receives Breakthrough Therapy Designation
GSK (GSK) announced that the US FDA (Food and Drug Administration) has granted Breakthrough Designation to its experimental antibody drug conjugate candidate GSK'227 for treating a rare kind of bone cancer.
Breakthrough Designation Therapy is aimed at advancing the development and review of drugs which have the potential to treat a serious condition and where preliminary evidence suggests a 'su...